Free cash flow remains deeply negative, with quarterly outflows escalating to $95.1 million in 2026Q4, partially obscured by $11.1 million in stock-based compensation.
| Cash from Operations | -407.31M | -375.87M | -214.23M | -188.19M | -106.11M | -83.33M | -53.36M | -28.55M | -128.3M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -8.36% | -75.46% | -13.83% | -77.35% | -27.34% | -56.17% | -86.91% | 77.75% | - |
| Net Income | -505.61M | -413.84M | -259.34M | -210.96M | -156.73M | -107.43M | -66.39M | -28.6M | -136.74M |
| Depreciation & Amortization | 409K | 377K | 231K | 193K | 126K | 998K | 21K | 10K | 0 |
| Stock-Based Compensation | 55.72M | 49.49M | 41.12M | 32.3M | 34.24M | 0 | 6.96M | 1.31M | 1.81M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 99K | 133K | 1.13M | 1.13M | 1.11M | 18.54M | 1.24M | -792K | 5.19M |
| Working Capital Changes | 42.06M | -12.03M | 2.63M | -10.85M | 15.14M | 4.57M | 4.81M | -474K | 1.44M |
| Change in Receivables | -1.4M | 2.97M | -4.56M | 12.22M | -11.72M | 2.5M | -83K | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -10.25M | 10.68M | 5.78M | -17.12M | 16.25M | 1.25M | 967K | 0 | 0 |
| Cash from Investing | -8K | -759K | -360K | -197K | -254K | -210K | -31K | -52K | 0 |
| Capital Expenditures | -8K | -759K | -360K | -197K | -254K | -210K | -31K | -52K | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 595.76M | 454.49M | 472.43M | 70.89M | 200.13M | 383.11M | 146.97M | 35.58M | 128.3M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | -3.19M | 37.91M | 0 | 0 |
| Equity Issued (Net) | 596.26M | 450M | 472.75M | 70.5M | 0 | 386.3M | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -504K | 4.49M | -318K | 385K | 200.13M | 0 | 109.07M | 35.58M | 128.3M |
| Net Change in Cash | 188.14M | 78.61M | 258.83M | -117.28M | 93.67M | 299.57M | 93.59M | 6.99M | 0 |
| Free Cash Flow | -407.32M | -376.63M | -214.59M | -188.39M | -106.37M | -83.54M | -53.39M | -28.6M | -128.3M |
| FCF Margin % | - | - | - | - | - | - | - | - | - |
| FCF Growth % | -8.15% | -75.52% | -13.91% | -77.11% | -27.33% | -56.47% | -86.68% | 77.71% | - |
| FCF per Share | -2.23 | -2.48 | -1.55 | -1.53 | -0.97 | -0.95 | -1.24 | -1.99 | -12.83 |
| FCF Conversion (FCF/Net Income) | 0.81x | 0.91x | 0.83x | 0.89x | 0.68x | 0.78x | 0.80x | 63720.98x | 0.94x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 2.39M | 1.2M | 509K | 0 | 0 | 0 | 61K | 0 | 0 |
Clinical trial execution failure
According to recent quarterly filings, Immunovant’s operating cash flow consistently trails net losses, with the company reporting a $95.1 million cash outflow against a $147.9 million net loss in 2026Q4, underscoring the persistent disconnect between accounting accruals and the actual cash required to sustain clinical operations.
The gap between net income and operating cash flow suggests that non-cash expenses, primarily stock-based compensation, are insufficient to bridge the burn rate. Investors should monitor this divergence as it indicates that the company's operational scale is expanding faster than its ability to manage cash-based working capital requirements.
As reported in financial statements, Immunovant’s free cash flow trajectory remains deeply negative, with quarterly outflows escalating from $47.2 million in 2024Q3 to $95.1 million by 2026Q4, reflecting the intensifying capital requirements necessary to support late-stage clinical development and the associated infrastructure for its FcRn pipeline.
The consistent negative FCF trajectory confirms that the company is entirely dependent on external financing to fund its research initiatives. This trend warrants further investigation into how long the current cash position can support these programs before additional dilutive capital raises become a structural necessity.
Based on the company's reported figures, working capital changes have fluctuated significantly, swinging from a $16.0 million outflow in 2025Q4 to a $41.5 million inflow in 2026Q4, which suggests that timing differences in vendor payments and clinical trial accruals are creating substantial quarter-to-quarter cash flow volatility.
This volatility appears to be a byproduct of the lumpy nature of clinical trial expenditures rather than operational efficiency. Analysts should interpret these swings as a sign of the company's limited control over the timing of cash outflows, which are dictated by the aggressive pace of trial enrollment.
Data from recent SEC filings reveals that stock-based compensation remains a significant non-cash add-back, totaling $11.1 million in 2026Q4, which effectively masks the true economic cost of talent retention required to maintain the company's competitive position in the highly specialized immunology research sector.
While these adjustments are standard, they obscure the reality that the company is essentially paying for its human capital through equity dilution rather than operational cash flow. This practice warrants further investigation into the long-term impact on shareholder value as the company continues to rely on this mechanism to preserve its cash reserves.
Quick answers to the most common questions about buying IMVT stock.
Immunovant, Inc. (IMVT) generated $-407.3M in net cash from operating activities in 2026. This reflects the cash generated directly from core business operations.
Immunovant, Inc. (IMVT) reported negative free cash flow of $407.3M in 2026, indicating capital requirements exceeded cash from operations.
Immunovant, Inc. (IMVT) spent $0.0M on capital expenditures in 2026. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.